Charles River Laboratories International, Inc.
CRL Healthcare Diagnostics & Research
Charles River Laboratories International, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $4.0 billion, down 0.85% from fiscal 2024.
- Revenue
- −2.20%
- EPS
- +530.3%
- Free cash flow
- +16.3%
- Total debt
- +11.8%
Quarter to September 2026, against a year earlier
Follow CRL
Alert me
Charles River Laboratories International, Inc. (CRL) P/B ratio
As of 5 November 2026, Charles River Laboratories International, Inc. (CRL) trades at a P/B ratio of 4.6×. Over the past ten years it has ranged from 1.6× (April 2025) to 9.9× (September 2021); the current reading is higher than 52% of that period. That is above the Diagnostics & Research industry median of 3.4× and above the Healthcare sector median of 2.3×.
P/B ratio, daily
Embed this chart
Annual newest first
| Period | P/B ratio | Change |
|---|---|---|
| FY2025 | 3.1× | 14.01% |
| FY2024 | 2.7× | (17.87%) |
| FY2023 | 3.3× | (10.51%) |
| FY2022 | 3.7× | (50.12%) |
| FY2021 | 7.5× | 27.69% |
| FY2020 | 5.8× | 28.60% |
| FY2019 | 4.5× | 10.54% |
| FY2018 | 4.1× | (18.03%) |
| FY2017 | 5.0× | 16.98% |
| FY2016 | 4.3× | (15.39%) |
Quarterly newest first
| Period | P/B ratio | Change |
|---|---|---|
| Sep 2026 | 4.4× | 14.02% |
| Jun 2026 | 3.8× | 33.53% |
| Mar 2026 | 2.9× | (8.11%) |
| Dec 2025 | 3.1× | 38.14% |
| 43 more quarters | Free account |
Against its own ten years
P/B ratio against peers
| Company | P/B ratio |
|---|---|
| GH Guardant Health, Inc. compare | n/m |
| ICLR ICON PLC compare | 1.7× |
| RVTY Revvity Inc. compare | 2.3× |
| QGEN QIAGEN N.V. compare | 3.1× |
| LH Labcorp Holdings Inc. compare | 3.3× |
| DGX Quest Diagnostics Incorporated compare | 3.5× |
| CRL Charles River Laboratories International, Inc. | 4.6× |
| ILMN Illumina, Inc. compare | 10.1× |
| MEDP Medpace Holdings, Inc. compare | 30.3× |
| Diagnostics & Research industry median | 3.4× |
| Healthcare sector median | 2.3× |
| Market median | 1.7× |
What P/B ratio is
Price to Book Value tells an investor how much the market pays for a company’s shares relative to the accounting net worth that belongs to common shareholders.
Stock Price ÷ (Common Equity (Total) (latest quarter) ÷ Shares (Basic, Weighted) (latest quarter))
More on CRL
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement